Our results showed that low levels of DDX55, ANXA1, PICAL, and AGRG6 before treatment, as well as elevated levels of CTRB1 pre-MSC treatment, were biomarkers for predicting response to MSC therapy in severe COVID-19 patients. This evidence concerns the gene CTRB1 and COVID-19.